{'fraction_non_alphanumeric': 0.028823058446757407, 'fraction_numerical': 0.018414731785428344, 'mean_word_length': 5.756756756756757, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An improved synthesis of indanocine and antiproliferative activity of 2‐benzylindanocine via microtubule destabilization

Indanocine, a potent anticancer investigational drug of National Cancer Institute‐USA, has been much discussed in recent years. Present communication aimed at total synthesis of indanocine and its close analogues. Total synthesis was improved by double yields than previously reported yields. Some of the benzylidene and 2‐benzyl derivatives with free rotation at C2 position exhibited potential cytotoxicities against various human cancer cell lines. Five such analogues exhibited potential antiproliferative effect against HCT‐116 and MIA PACA‐2 cell lines. Benzylindanocine 12i induced microtubule destabilization by occupying colchicine binding pocket of β‐tubulin. It also exhibited anti‐inflammatory activity by down‐regulating IL‐6 and TNF‐α. In Ehrlich ascites carcinoma model, 12i reduced 78.4% of EAC tumour in Swiss albino mice at 90 mg/kg (i.p.) dose. Further, in in vivo safety studies, 12i was found to be safe to rodents up to 1,000 mg/kg dose. Concomitant anticancer and anti‐inflammatory activity of benzylindanocine is distinctive, which suggests its further optimization for better efficacy and druggability.